PAI HOLDINGS announced the approval of its ANDA by the FDA for a new generic drug on July 28, setting the stage for imminent market entry and potential revenue growth as it challenges the brand-labeled leader. This regulatory milestone grants the company 180 days of market exclusivity, providing a significant near-term revenue boost while addressing a critical need in the pharmaceutical sector.